Hannah Clarke

Neal D. Shore, MD, FACS, shares key findings from a post hoc analysis of the EMBARK trial showing that sustained PSA responses are possible following only 9 months of treatment with enzalutamide plus leuprolide.

Robert J. Motzer, MD, discusses the scientific rationale for the LITESPARK-011 study, its design and key findings, and how this combination could potentially influence treatment strategies in renal cell carcinoma.

Results from the AMPLIFY trial are intended to support an FDA submission seeking approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent for BCR of prostate cancer.

ImmunityBio has resubmitted an sBLA for the combination following an FDA request for updated efficacy data.

NDV-01, a sustained-release intravesical combo, delivered durable 12‑month complete responses in high-risk NMIBC, particularly among patients with BCG-unresponsive disease.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

FX-909, a first-in-class PPARγ inverse agonist, demonstrated manageable toxicity and preliminary antitumor activity in patients with advanced urothelial carcinoma.

ImmunityBio plans to submit a biologics license application to the FDA by Q4 of 2026.

The PDUFA target action date is set for October 4, 2026.

The target action date for the application is June 19, 2026.

A recap of the FDA submissions and regulatory decisions in urology from February 2026.

PROSTOX Standard estimates the risk of late genitourinary toxicity following conventionally fractionated or moderately hypofractionated radiation therapy for localized prostate cancer.

AKY-1189 is currently under investigation in the phase 1b NECTINIUM-2 trial.

Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.

Data showed that measurement of ctDNA and utDNA could identify patients who are most likely to remain cancer-free following systemic therapy.

The combination of enfortumab vedotin plus pembrolizumab extended event-free and overall survival in patients with MIBC who are ineligible for cisplatin-based chemotherapy.

Across 7 randomized trials, 177Lu-PSMA-617 significantly prolonged progression-free survival vs standard therapies, with no significant difference in adverse events.

The agent was granted conditional marketing authorization based on data from the phase 2/3 QUILT-3.032 trial.

Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US.

64Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of prostate cancer lesions per patient compared with 68Ga-PSMA-11 PET/CT.

Despite early termination of the trial, its results provide scientific rationale for further investigation into targeting alternative AR domains in mHSPC.

FDA lifts boxed warnings on 6 menopausal hormone therapies following a review of the evidence on risks and benefits.

A newly published meta-analysis found that adding metastasis-directed therapy to standard of care was associated with extended progression-free survival in oligometastatic prostate cancer, without adding significant safety risks.

The phase 2 Alliance A222001 trial demonstrated that oxybutynin led to clinically meaningful improvements in hot flash frequency and quality of life among men receiving hormone therapy for prostate cancer.

The findings offer insights into how treatment may be optimized using PSMA-PET/CT results.

The following FAQs highlight key guideline recommendations relevant to clinicians regarding the early detection of prostate cancer.

The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of NEO-811 in clear cell renal cell carcinoma.

The sildenafil oral film is expected to be commercially available in the US in March 2026.